Navigation Links
Daiichi Sankyo And Coherus BioSciences Establish Strategic Collaboration To Develop And Commercialize Biosimilar Candidates
Date:5/7/2012

REDWOOD CITY, Calif. and TOKYO, May 7, 2012 /PRNewswire/ -- Coherus BioSciences, Inc (hereafter, Coherus BioSciences) and Daiichi Sankyo, Co. Ltd. (hereafter, Daiichi Sankyo; TSE 4568) announced today the execution of an exclusive agreement to develop and commercialize biosimilar forms of etanercept and rituximab in certain Asian countries including Japan.

(Logo: http://photos.prnewswire.com/prnh/20120507/SF01448LOGO)

Under the terms of the agreement, Daiichi Sankyo and Coherus BioSciences will work together to develop, manufacture and commercialize  biosimilar forms of etanercept and rituximab developed by Coherus BioSciences. Upon marketing approval, Daiichi Sankyo will commercialize these products in Japan, South Korea and Taiwan. Coherus has retained all additional development and commercial rights outside of the licensed territories.  Specific financial terms of the agreement were not disclosed.

"This collaboration to develop and commercialize these biosimilar candidates with a leading global healthcare company such as Daiichi Sankyo is a significant strategic event for Coherus BioSciences and validates our unique business model strategy," said Denny Lanfear, Chief Executive Officer.  "This agreement demonstrates that our strategy and model position us well to make a major impact toward providing access to biosimilar therapies for patients on a global basis."

"Coherus BioSciences has established an outstanding business model, a very experienced biologic development team and outstanding capabilities," said Joji Nakayama, President & CEO of Daiichi Sankyo. "By creating an opportunity for an early entry into the biosimilars market, this agreement will strengthen our internal platform for manufacturing and developing biopharmaceuticals, leading directly to the introduction of other biosimilars therapies in the future."

Sagent Advisors
'/>"/>

SOURCE Coherus BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
2. Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs
3. DAIICHI SANKYO EUROPE GmbH Selects DATATRAK eClinical™ for Pan-European Systolic Hypertension Study
4. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
5. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
6. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
7. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
8. Milestone Biosciences, LLC Further Strengthens Executive Management Team
9. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
10. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
11. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... 2014 Audacity, a leading California-based health ... of the Huntsworth Health Group, is proud to announce ... In her role, Gonzales will serve as Senior Vice ... honored to welcome a talent of Jamie’s caliber to ... Fraikin. “She is a proven healthcare innovation leader and ...
(Date:12/17/2014)... Dec. 17, 2014   Synageva BioPharma Corp. ... therapeutic products for rare disorders, announced today its presentation ... in San Francisco, CA. ... Executive Officer, will present on Monday, January 12, 2015, ... will be webcast live and may be accessed from ...
(Date:12/15/2014)... Agritech Limited (NASDAQ GS: SEED) (" Origin ", or the ... China , today announced that the Company ... 30, 2014, before the market opens on Thursday, January 8, ... January 8, 2015, at 8:00 a.m. ET / 9:00 p.m. ... To participate in the call, please dial +1-888-346-8982 in ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3
... CALGARY, June 4 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc.,(TSX:SBS), ... for metabolic and cardiovascular diseases, today announced that,Andrew ... present a corporate,update at the Needham & Company, ... presentation is scheduled on Wednesday,June 11 at 2:30 ...
... In a plan designed to develop,educational opportunities ... Tiger Woods Learning Center (TWLC) are collaborating to ... report by the National,Research Council studied the declining ... likely to have increased scientific interests if they ...
... Medical Corporation,(OTC Bulletin Board: CONX), a worldwide developer ... AspirinWorks(R) Test at the,American Diabetes Association,s 68th Scientific ... 7 - 9, 2008, at the Moscone Convention,Center ... first time the AspirinWorks test will be exhibited ...
Cached Biology Technology:LI-COR(R) Biosciences and Tiger Woods Learning Center Collaborate to Develop High School Curriculum in Genetics 2Corgenix to Exhibit AspirinWorks(R) Test at ADA 2008 Meeting in San Francisco 2Corgenix to Exhibit AspirinWorks(R) Test at ADA 2008 Meeting in San Francisco 3
(Date:11/21/2014)... -- C-Labs LLC, a leading provider of remote and ... announced the appointment of John Traynor to ... advisor to the firm, Mr. Traynor will now oversee ... out of the C-Labs office in Redmond, ... , Chief Executive Officer. Photo - ...
(Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
(Date:11/15/2014)... 2014  While we may still be a few years ... "Star Trek" to gain instant access to all that ailed ... smartphones and tablets for monitoring and measuring our health are ... may seem a tad Orwellian to some, but a new ... these technological opportunities into their healthcare regime. These ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... at the Kimmel Cancer Center at Jefferson (KCC) (insert ... developed potentially game-changing diagnostic and prognostic genetic tests shown ... clinically-relevant cancers. The team, led by ... the KCC and the Chair of the Department ...
... a $480,000 gift from the Emily Landecker Foundation. The ... Astrobiology, which will support graduate students in the School ... astrobiology. The fellowship is named in honor of Ferris, ... a senior research professor, and a member of the ...
... of two University of California, Berkeley, scientists who are part ... complete genome sequence. "This genome has revolutionized our studies," ... cell biology who lobbied for inclusion of the leech in ... animals in order to learn what they have in common ...
Cached Biology News:Game changing diagnostic & prognostic prostate cancer genetic tests revealed by Jefferson 2Game changing diagnostic & prognostic prostate cancer genetic tests revealed by Jefferson 3Rensselaer awarded gift to establish fellowship in astrobiology 2What do leeches, limpets and worms have in common? Now, a sequenced genome 2What do leeches, limpets and worms have in common? Now, a sequenced genome 3
... biomarker discovery projects require screening through ... distinguish clinically relevant data from normal ... Manager is now available to help ... and data flood inherent to biomarker ...
This free-standing laminar flow hood provides a vertical flow of HEPA-filtered air to create a clean processing area. It includes a fluorescent light and motorized sliding shield. Options include wor...
This modular laminar flow hood forces air through a 99.99% efficient HEPA filter to create a clean processing area. Configurations are available with vertical or horizontal flow; options include a wo...
... provider of X-ray crystallography services for ... services to its pharmaceutical and biotechnology ... of drug-like fragments to the active ... allowing scientists to develop novel, high-affinity ...
Biology Products: